JAGSNPHARM vs SPARC: Stock Comparison
SUN PHARMA ADV.RES.CO.LTD is the larger company by market capitalisation. JAGSONPAL PHARMACEUTICALS shows a higher dividend yield and lower leverage, while SUN PHARMA ADV.RES.CO.LTD shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
JAGSNPHARM leads 4; SPARC leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | JAGSNPHARM | SPARC |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | JAGSNPHARM | SPARC |
|---|---|---|
| Live Price | ₹215.39 | ₹178.55 |
| Day Change | -2.95% | -2.42% |
| Volume | 34,191 | 1.93 L |
| 52-Week High | ₹264.5 | ₹289 |
| 52-Week Low | ₹155 | ₹108 |
| Distance from 52W High | -18.57% | -38.22% |
Valuation
| Metric | JAGSNPHARM | SPARC |
|---|---|---|
| Market Cap | ₹1,428 Cr | ₹5,793 Cr |
| P/E Ratio | 32.35x | 3.75x |
| P/B Ratio | 6.09x | 4.44x |
| EPS | ₹2 | ₹-0.64 |
| Book Value | ₹41.95 | ₹41.26 |
| Dividend Yield | 1.8% | 0% |
Growth
| Metric | JAGSNPHARM | SPARC |
|---|---|---|
| Revenue Growth (TTM YoY) | 9.6% | 6,716.8% |
| EPS Growth (TTM YoY) | 23.8% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | JAGSNPHARM | SPARC |
|---|---|---|
| ROE | 15.6% | 116.01% |
| ROCE | 16.48% | 83.81% |
| Net Margin | 15% | 82.65% |
| Operating Margin | 20.38% | 84.46% |
| Debt to Equity | 0x | 0.42x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | JAGSNPHARM | SPARC |
|---|---|---|
| Promoter Holding | 25.46%▼ 0.09 pp | 65.67% |
| FII Holding | 2.14%▼ 0.16 pp | 3.75%▼ 0.15 pp |
| DII Holding | 1.65%▲ 1.03 pp | 0.11%▲ 0.02 pp |
| Public Holding | 27.4%▼ 0.63 pp | 30.48%▲ 0.15 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: JAGSONPAL PHARMACEUTICALS and SUN PHARMA ADV.RES.CO.LTD.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.